EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 13 filers reported holding EVOKE PHARMA INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $48,000 | -55.1% | 87,925 | +7.3% | 0.01% | -50.0% |
| Q3 2021 | $107,000 | +64.6% | 81,975 | +72.8% | 0.01% | +55.6% |
| Q2 2021 | $65,000 | -61.3% | 47,431 | -27.0% | 0.01% | -71.9% |
| Q4 2020 | $168,000 | +60.0% | 65,004 | +190.4% | 0.03% | +100.0% |
| Q3 2020 | $105,000 | -27.1% | 22,382 | -64.9% | 0.02% | +220.0% |
| Q3 2016 | $144,000 | – | 63,768 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |